source
- London startup Oyster Therapeutics raises $60M to develop oral tau degraders for Alzheimer’sOyster Therapeutics, a London‑based biotech, announced it has closed a $60 million Series A‑2 financing round. The round was led by 4BIO Capital, a life‑science venture capital firm, with addition…
- Democrats demand unredacted drug pricing agreements from pharma firms after midterm victoriesCongressional Democrats have intensified scrutiny of pharmaceutical pricing agreements made under the previous administration. On Monday they sent letters to every drug maker that entered a most f…